

▪

Tissue distribution of Suvorexant in three postmortem cases

Brian Waters, Kenji Hara, Natsuki Ikematsu, Mo Takayama, Aya Matsue, Masayuki Kashiwagi and Shin-ichi Kubo
Fukuoka University, Japan

S a e e f e P b e : Suvorexant (Belsomra®) is a relatively new insomnia medication that has been available in the US and Japan since 2014. It is a dual orexin receptor antagonist that promotes sleep by inhibiting the binding of orexin neurons to the OX1R and OX2R receptors. In this report, we describe the detection and quantitation of Suvorexant from the postmortem